Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
Type:
Grant
Filed:
April 15, 2016
Date of Patent:
May 22, 2018
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
Type:
Grant
Filed:
April 15, 2016
Date of Patent:
May 22, 2018
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
Type:
Grant
Filed:
April 15, 2016
Date of Patent:
May 22, 2018
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Abstract: The invention relates to a composition comprising buprenorphine and ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Type:
Application
Filed:
November 2, 2017
Publication date:
March 1, 2018
Applicant:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Sean Cunningham, Seamus Mulligan, Michael Myers
Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent.
Type:
Grant
Filed:
October 13, 2015
Date of Patent:
January 9, 2018
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
November 28, 2017
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
Abstract: Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (Dv50) of less than about 1000 nm. Also described herein are methods of treatment using the aforementioned composition, and methods of making the aforementioned composition.
Type:
Application
Filed:
February 16, 2017
Publication date:
August 17, 2017
Applicant:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Tarek A. ZEIDAN, David MANSER, Kristopher Perkin, Philip CRESSWELL, Magali HICKEY, Brian STEINBERG
Abstract: The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.
Type:
Grant
Filed:
July 21, 2016
Date of Patent:
June 20, 2017
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
Abstract: The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X?. In one embodiment, the present invention provides a prodrug compound of Formula I: where R1-R5 are defined in the written description of the invention.
Type:
Grant
Filed:
December 23, 2010
Date of Patent:
June 6, 2017
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Örn Almarsson, Laura Cook Blumberg, Julius F. Remenar
Abstract: The present application relates methods for treating a depressive symptom comprising administering an effective amount of a ? opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.
Type:
Grant
Filed:
May 23, 2014
Date of Patent:
May 23, 2017
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
Type:
Grant
Filed:
May 22, 2015
Date of Patent:
March 7, 2017
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
Type:
Grant
Filed:
June 7, 2016
Date of Patent:
January 31, 2017
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.